Diasorin S.p.a Stock News

DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferenc

DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2022 Earnings Conference Call March 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen

DiaSorin S.p.A. is an Italian healthcare company that develops, produces, and sells reagent kits and analyzer instruments mostly used to detect patients' diseases. DiaSorin benefited from the outbreak

DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2022 Earnings Conference Call August 3, 2022 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen

DiaSorin S.p.A. (OTCPK:DSRLF) Q1 2022 Earnings Conference Call May 6, 2022 11:30 AM ET Company Participants Carlo Rosa – Chief Executive Officer Piergiorgio Pedron – Chief Financial Officer Confer

DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript

DiaSorin S.p.A. (OTCMKTS:DSRLF) Equities research analysts at Jefferies Financial Group cut their FY2021 EPS estimates for DiaSorin in a note issued to investors on Sunday, December 19th. Jefferies Financial Group analyst P. Welford now anticipates that the company will post earnings per share of $7.07 for the year, down from their previous estimate of []

Italy''s DiaSorin sees 60% plunge in COVID-19 revenue next year

Italian diagnostics firm DiaSorin forecast weaker 2022 sales and a near 60% plunge in COVID-19 revenue, with the rapid rollout of vaccines likely to bring the pandemic under control and crimp demand f

Chemiluminescence Immunoassay Market The chemiluminescence immunoassay market was valued at USD 6000 million in 2019 and is expected to grow with a CAGR of 7.5% during the forecast period. Immunoassays are bio analytical procedures which are used in the diagnosis of various disease. The

The global Retrovirus Testing market size is projected a CAGR of 5.8% during 2021-2027. The global retrovirus testing market is being driven by the high prevalence of HIV and increased awareness regarding HIV diagnosis. The global retrovirus testing market is

"Helicobacter Pylori Diagnostics includes tests and mechanisms used to decide if one has an H.pylori infection. Tests include blood tests in which investigation of a blood sample can reveal evidence of an active or previous H. pylori infection in the

DiaSorin S.p.A. (OTCMKTS:DSRLF) has been given a consensus rating of Hold by the seven brokerages that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating on the company. The average 12 month []

Carlo Rosa, CEO of DiaSorin, tells CNBC that the company's Covid-19 tests can detect the omicron variant and discusses what the impact of the new variant will be on mass testing.

DUBLIN--(BUSINESS WIRE)--The "Endocrine Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com''s offering. The global endocrine testing market reached a value of US$ 10 Billion in 2020. Looking forward, the publisher expects the market to grow at a CAGR of 8.7% during 2021-2026. Companies Mentioned Abbott Laboratories Agilent Technologies Inc. Bio-Rad Laboratories Inc. BioMerieux SA DiaSorin S.p.A. F. Hoff